ES2241653T3 - Utilizacion de un vector adenoviral de replicacion deficiente para la fabricacion de un medicamento destinado a estimular la respuesta inmune de celulas t cd8+ antigeno. - Google Patents
Utilizacion de un vector adenoviral de replicacion deficiente para la fabricacion de un medicamento destinado a estimular la respuesta inmune de celulas t cd8+ antigeno.Info
- Publication number
- ES2241653T3 ES2241653T3 ES00960857T ES00960857T ES2241653T3 ES 2241653 T3 ES2241653 T3 ES 2241653T3 ES 00960857 T ES00960857 T ES 00960857T ES 00960857 T ES00960857 T ES 00960857T ES 2241653 T3 ES2241653 T3 ES 2241653T3
- Authority
- ES
- Spain
- Prior art keywords
- antigen
- cells
- administration
- epitope
- immune response
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 48
- 102000036639 antigens Human genes 0.000 title claims abstract description 48
- 108091007433 antigens Proteins 0.000 title claims abstract description 48
- 239000013598 vector Substances 0.000 title claims abstract description 22
- 230000028993 immune response Effects 0.000 title claims abstract description 21
- 230000010076 replication Effects 0.000 title claims abstract description 21
- 230000002950 deficient Effects 0.000 title claims abstract description 20
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 8
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 8
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 8
- 230000008901 benefit Effects 0.000 claims abstract description 4
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 4
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims abstract description 4
- 230000037452 priming Effects 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 20
- 238000007918 intramuscular administration Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 5
- 238000002649 immunization Methods 0.000 description 40
- 230000003053 immunization Effects 0.000 description 40
- 241000701161 unidentified adenovirus Species 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 23
- 229960005486 vaccine Drugs 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 16
- 241000224017 Plasmodium berghei Species 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 14
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 210000004988 splenocyte Anatomy 0.000 description 10
- 230000005867 T cell response Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 8
- 201000004792 malaria Diseases 0.000 description 8
- 108010041986 DNA Vaccines Proteins 0.000 description 7
- 229940021995 DNA vaccine Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000003046 sporozoite Anatomy 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000003248 secreting effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 241000209219 Hordeum Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 206010072219 Mevalonic aciduria Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 101150052200 CS gene Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700647 Variola virus Species 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 229940065638 intron a Drugs 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000271566 Aves Species 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010006025 bovine growth hormone Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700004715 Flavivirus NS1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001084338 Listeria sp. Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010028253 Measles virus nucleoprotein Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 101000916458 Plasmodium berghei Circumsporozoite protein Proteins 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 229940023860 canarypox virus HIV vaccine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- -1 carrier Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- FEBNTWHYQKGEIQ-BIMULSAOSA-N nardin Natural products C[C@H]1CC[C@H](C=C(/C)C(=O)O)C2=C(C)CC[C@@H]12 FEBNTWHYQKGEIQ-BIMULSAOSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- FEBNTWHYQKGEIQ-UHFFFAOYSA-N valerenic acid Chemical compound CC1CCC(C=C(C)C(O)=O)C2=C(C)CCC12 FEBNTWHYQKGEIQ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9922361.2A GB9922361D0 (en) | 1999-09-21 | 1999-09-21 | Generating an immune response to an antigen |
| GB9922361 | 1999-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2241653T3 true ES2241653T3 (es) | 2005-11-01 |
Family
ID=10861351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00960857T Expired - Lifetime ES2241653T3 (es) | 1999-09-21 | 2000-09-20 | Utilizacion de un vector adenoviral de replicacion deficiente para la fabricacion de un medicamento destinado a estimular la respuesta inmune de celulas t cd8+ antigeno. |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1612269A1 (enExample) |
| JP (1) | JP2003509470A (enExample) |
| CN (1) | CN1391609A (enExample) |
| AT (1) | ATE295421T1 (enExample) |
| AU (1) | AU762894B2 (enExample) |
| BR (1) | BR0014138A (enExample) |
| CA (1) | CA2384806A1 (enExample) |
| DE (1) | DE60020136T2 (enExample) |
| DK (1) | DK1214416T3 (enExample) |
| ES (1) | ES2241653T3 (enExample) |
| GB (1) | GB9922361D0 (enExample) |
| WO (1) | WO2001021201A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| JP2003530307A (ja) | 1999-07-06 | 2003-10-14 | メルク・アンド・カンパニー・インコーポレーテッド | ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン |
| US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
| JP4654026B2 (ja) * | 2002-05-20 | 2011-03-16 | 独立行政法人科学技術振興機構 | Ｂｃｇワクチンとその利用 |
| EP1553983A2 (en) | 2002-10-23 | 2005-07-20 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| CN100410382C (zh) * | 2006-08-18 | 2008-08-13 | 上海交通大学医学院 | 一种可诱生细胞免疫应答的共表达载体和真核表达载体 |
| JP5646851B2 (ja) * | 2006-11-17 | 2014-12-24 | ジェネトロニクス，インコーポレイティド | エレクトロポレーション支援ワクチン投与及び追加投与を用いた免疫応答の増強方法 |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| GB0706912D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel viral vaccines |
| CA2699465C (en) * | 2007-09-14 | 2017-11-28 | Institut Pasteur | Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use |
| GB0823497D0 (en) | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| MX380483B (es) * | 2012-10-28 | 2025-03-12 | Bavarian Nordic As | Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes. |
| EP3595705A1 (en) | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| MX2022004484A (es) * | 2019-10-16 | 2022-07-19 | Cancer Research Tech Ltd | Vector para el tratamiento de cancer. |
| EP4444347A1 (en) | 2021-12-07 | 2024-10-16 | Barinthus Biotherapeutics (UK) Limited | Vaccine boost methods and compositions |
| WO2024218165A1 (en) | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
-
1999
- 1999-09-21 GB GBGB9922361.2A patent/GB9922361D0/en not_active Ceased
-
2000
- 2000-09-20 BR BR0014138-0A patent/BR0014138A/pt not_active Application Discontinuation
- 2000-09-20 CA CA002384806A patent/CA2384806A1/en not_active Abandoned
- 2000-09-20 ES ES00960857T patent/ES2241653T3/es not_active Expired - Lifetime
- 2000-09-20 WO PCT/GB2000/003601 patent/WO2001021201A2/en not_active Ceased
- 2000-09-20 AU AU73024/00A patent/AU762894B2/en not_active Ceased
- 2000-09-20 EP EP05009308A patent/EP1612269A1/en not_active Withdrawn
- 2000-09-20 DE DE60020136T patent/DE60020136T2/de not_active Revoked
- 2000-09-20 JP JP2001524625A patent/JP2003509470A/ja not_active Withdrawn
- 2000-09-20 AT AT00960857T patent/ATE295421T1/de not_active IP Right Cessation
- 2000-09-20 EP EP00960857A patent/EP1214416B1/en not_active Revoked
- 2000-09-20 CN CN00815933A patent/CN1391609A/zh active Pending
- 2000-09-20 DK DK00960857T patent/DK1214416T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| BR0014138A (pt) | 2002-05-21 |
| WO2001021201A3 (en) | 2001-10-18 |
| DK1214416T3 (da) | 2005-08-29 |
| DE60020136D1 (de) | 2005-06-16 |
| DE60020136T2 (de) | 2006-02-23 |
| CA2384806A1 (en) | 2001-03-29 |
| JP2003509470A (ja) | 2003-03-11 |
| EP1612269A1 (en) | 2006-01-04 |
| EP1214416A2 (en) | 2002-06-19 |
| AU7302400A (en) | 2001-04-24 |
| EP1214416B1 (en) | 2005-05-11 |
| ATE295421T1 (de) | 2005-05-15 |
| AU762894B2 (en) | 2003-07-10 |
| CN1391609A (zh) | 2003-01-15 |
| GB9922361D0 (en) | 1999-11-24 |
| WO2001021201A2 (en) | 2001-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gilbert et al. | Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime–boost immunisation regimes | |
| EP1335023B1 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| ES2345604T3 (es) | Uso del vector virus pox carente de replica para impulsar la respuesta inmune de celula t cd4+ al antigeno. | |
| AU762894B2 (en) | Use of replication-deficient adenoviral vector to boost CD8+ T cell immune response to antigen | |
| Moore et al. | Progress in DNA‐based heterologous prime‐boost immunization strategies for malaria | |
| AU2001286109A1 (en) | Use of replication-deficient poxvirus vector to boost CD4+T cell immune response to antigen | |
| Gilbert et al. | Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations | |
| JP2010523138A (ja) | 免疫原性組成物 | |
| US20100322896A1 (en) | Molecular adjuvant | |
| EP3442570A1 (en) | Prime target | |
| AU775973B2 (en) | Methods and reagents for vaccination which generate a CD8 T cell immune response | |
| AU2004203141B2 (en) | Methods and reagents for vaccination which generate CD8 T cell immune response |